Related Experiment Video

Updated: Aug 13, 2026

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Drugs active against growth factor and oncogene phosphatidylinositol signalling pathways

G Powis1

  • 1Arizona Cancer Center, Tuscon 85724.

Seminars in Cancer Biology
|December 1, 1992
PubMed

Insights

New anticancer drugs target multiple intracellular signaling pathways. Ether lipids and myo-inositol antagonists offer novel strategies against cancer by inhibiting key growth pathways, sparing normal cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Intracellular signaling pathways driven by growth factors and oncogenes are crucial in cancer.
  • Targeting oncoproteins directly is challenging due to selectivity issues.
  • Inhibiting single signaling pathways may spare normal cells due to pathway degeneracy.

Purpose of the Study:

  • To explore novel antiproliferative drug classes targeting intracellular signaling.
  • To discuss strategies for developing selective and effective cancer therapeutics.
  • To highlight the potential of multi-target inhibitors and pathway antagonists.

Main Methods:

  • Review of existing literature on anticancer drug development.
  • Analysis of ether lipid anticancer drugs and their mechanisms.
  • Examination of D-3-deoxy-3-substituted myo-inositols and phosphatidylinositols as signaling antagonists.

Main Results:

  • Ether lipid anticancer drugs inhibit multiple signaling points including phosphatidylinositol phospholipase C, protein kinase C, intracellular Ca2+ release, and phosphatidylinositol-3'-kinase.
  • New compounds, D-3-deoxy-3-substituted myo-inositols and phosphatidylinositols, act as antagonists of myo-inositol signaling.
  • Multi-target inhibition and pathway antagonism show promise for cancer therapy.

Conclusions:

  • Targeting multiple components of intracellular signaling pathways offers a promising strategy for novel anticancer drugs.
  • Ether lipids and myo-inositol analogs represent viable classes of antiproliferative agents.
  • Developing drugs that modulate signaling pathways can overcome limitations of direct oncoprotein targeting.

More Related Videos

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: